Evaluation of Versatile Intelligent Staining Technology (VIST) and Spectral Flexible Imaging (SFI) for Detection and Optical Characterization of Colorectal Lesions: A Prospective Randomized Controlled Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAlexandre Vontobel Padoin

About this trial

This prospective randomized controlled study aims to evaluate the diagnostic accuracy of Versatile Intelligent Staining Technology (VIST) and Spectral Flexible Imaging (SFI) for detection and optical characterization of colorectal lesions during colonoscopy. The performance of VIST and SFI will be compared with high-definition white light endoscopy (WLE), using histopathology as the reference standard and established endoscopic classifications (Paris, Kudo, and JNET). The study will also assess adenoma detection rate, serrated lesion detection, inter- and intraobserver agreement, and procedure-related metrics.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

Undergoing screening or surveillance colonoscopy

Adequate bowel preparation (Boston Bowel Preparation Scale ≥6, with ≥2 per segment)

Ability to understand and sign informed consent

Disqualifiers

History of inflammatory bowel disease (Crohn's disease or ulcerative colitis)

Prior colorectal resection

Colorectal stenosis preventing scope progression

Pregnancy or breastfeeding

Trial design

Design model

Parallel

Treatments tested in this trial

  • White Light Endoscopy

    Device

    Colonoscopy performed using high-definition white light imaging.

  • Versatile Intelligent Staining Technology

    Device

    Colonoscopy performed using Versatile Intelligent Staining Technology (VIST).

  • Spectral Flexible Imaging

    Device

    Colonoscopy performed using Spectral Flexible Imaging (SFI).

Treatment groups

990 Participants
are divided into 3 treatment groups
Group A: White Light Endoscopy (WLE)Active comparator 1 intervention
Group B: Versatile Intelligent Staining Technology (VIST)Experimental treatment 1 intervention
Group C: Spectral Flexible Imaging (SFI)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Adenoma Detection Rate (ADR)

Proportion of participants with ≥1 colorectal polyp detected during the first-look withdrawal phase using the allocated imaging modality.

Time frame
During index colonoscopy.

Secondary outcomes

1

Serrated Lesion Detection Rate

Proportion of participants with ≥1 serrated lesion (e.g., sessile serrated lesion or hyperplastic polyp) detected during the first-look withdrawal phase using the allocated imaging modality, with histopathology confirmation when available.

Time frame
During index colonoscopy.
2

Diagnostic Accuracy for Optical Characterization (Neoplastic vs Non-neoplastic)

Sensitivity, specificity, PPV, NPV, and overall accuracy of optical diagnosis for neoplastic versus non-neoplastic colorectal lesions, using histopathology as the reference standard.

Time frame
During index colonoscopy with post-procedure histopathology results.
3

Agreement Between Optical Diagnosis and Histopathology

Agreement (Cohen's kappa) between in vivo optical diagnosis and histopathology for colorectal lesions.

Time frame
During index colonoscopy with post-procedure histopathology results.
4

Concordance of Endoscopic Classifications With Histopathology

Agreement (Cohen's kappa) between endoscopic classifications (Paris, Kudo pit pattern, and JNET) assigned in vivo and histopathology.

Time frame
During index colonoscopy with post-procedure histopathology results.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Alexandre Vontobel Padoin

Lead sponsor

Pontificia Universidade Católica do Rio Grande do Sul

Sponsor institution

Hospital Sao Lucas da PUCRS

Collaborator

This trial is not recruiting at the moment. You can still explore other options: